Loading Quotes...


Registration is open for the Virtual Fall 2021 Group Meeting (October 20-22) More Here

Read the latest issue of our News from ECOG-ACRIN blog

Cancer doesn’t stop for COVID, and neither should cancer screening or treatment Advocacy Blog

Our clinical trials are enrolling patients during the pandemic More Here

Question about COVID19? Send an email

Latest News

Adjuvant therapy with sunitinib or sorafenib did not improve disease-free survival or overall survival in patients with sarcomatoid renal cell carcinoma, according to a post hoc analysis from study E2805 by Jose A. Karam, MD, FACS, and colleagues. September 4, 2021. British Journal of Urology International


Entinostat does not overcome endocrine resistance in advanced breast cancer, as Roisin Connolly and colleagues report in the final results of the E2112 trial. August 17, 2021. Cancer Therapy Advisor



Matchmakers: How Basket Trials Match Patients With Drugs Based on Their Tumors. Features interviews with patients, NCI-MATCH, and group co-chair Peter O’Dwyer, MD. July 14, 2021. CURE 



50,000 women have joined the TMIST breast cancer screening trial. This  trial is rapidly increasing despite the worldwide pandemic. July 15, 2021. Read More


Suresh Ramalingam in an article noting his same-day appointments as director of Emory Cancer Center and editor of Cancer. “I’ve been part of ECOG-ACRIN from the days of my fellowship training. Participation and active engagement within the groups have been a major reason for my career success. I’ve been fortunate to be entrusted with multiple leadership roles at ECOG-ACRIN.” July 9, 2021. The Cancer Letter

The latest findings from the TAILORx trial for women with early breast cancer show that poor social and physical well-being, along with co-morbid depression, were significant risk factors for premature discontinuation of hormone therapy, as reported by trial participants. Betina R. Yanez, PhD (Northwestern University), first author. June 17, 2021. JAMA Oncology


Kathy D. Miller, MDFor residual triple negative breast cancer, post-chemo, capecitabine should be offered. This commentary video by Kathy D. Miller, MD, discusses the results of the EA1131 phase III trial. June 15, 2021. Medscape



RSClin tool, validated with TAILORx data, uses clinicopathologic, genomic features to predict chemo benefit in early breast cancer. June 11, 2021. Clinical Oncology News


Do patients with mantle cell lymphoma require autologous stem cell transplant as consolidation therapy? Narendranath Epperla, MD, MS (Ohio State University) explains that the phase III trial EA4151 will help answer this question. June 11, 2021. OncLive


ECOG-ACRIN deputy chair, TAILORx lead investigator, and internationally renowned breast cancer and HIV-associated malignancy expert Joseph A. Sparano, MD, joins Mount Sinai. June 8, 2021. Read Press Release


E1411 lead investigator Mitchell R. Smith discusses the trial results at ASCO 2021. This trial focused on older patients with mantle cell lymphoma. June 9, 2021. OncLive



Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.

YouTube Highlights

View our YouTube channel for these and other videos:



Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.


Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair
img img